Investment Type: Venture Capital
Portfolio 6
| Date | Name | Website | Total Raised | Location |
| 16.05.2023 | Boundless ... | boundlessb... | $251.4M | United Sta... |
| 06.05.2023 | ITM Isotop... | itm-radiop... | $322.13M | Germany, B... |
| 02.08.2022 | IDRx | idrx.com | $122M | United Sta... |
| 22.09.2021 | Hexagon Bi... | hexagonbio... | $232.3M | United Sta... |
| 24.08.2021 | Atavistik | atavistikb... | $60M | United Sta... |
| 07.10.2020 | A2 Biother... | a2biothera... | $71.5M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cockta... | a16z.com/2... |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity fund... | archive.ci... |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity fund... | citybizlis... |
| 21.07.2016 | Nextech Invest Closes Oncology Fund IV, at $64M | Nextech Invest Ltd., a Zurich, Switzerland-based specialist oncology private equity investor, closed... | finsmes.co... |
| 11.05.2014 | ImaginAb Raises $21M in Series B Funding | ImaginAb, an Inglewood, CA-based clinical stage biotech company, raised $21m in Series B funding. T... | finsmes.co... |
| 08.01.2014 | Blueprint Medicines Completes $25M Series B Financing | Blueprint Medicines, a Cambridge, MA-based oncology company, completed a $25m Series B financing. T... | finsmes.co... |
| 17.12.2013 | Rahmenbedingungen für Börsengänge sind derzeit gut | In Sachen Börsengänge hat sich 2013 vor allem der US-Markt dynamisch entwickelt: Die Zahl der Börs... | startuptic... |
| 05.12.2013 | Dispute between entrepreneurs and venture capitalists | The panel discussion at the i-net event started with a statement of Michael Bornhäusser. He is Pre... | startuptic... |
| 17.12.2012 | Cancer therapeutic that causes “executioner” protein to kill... | The latest financing follows a $6 million fresh capital raise last year. In October 2010, it raised ... | medcitynew... |
| 27.03.2012 | ImaginAb Completes $12.5M Series A Financing | ImaginAb, Inc., a Los Angeles, CA-based clinical-stage company developing in vivo imaging agents for... | finsmes.co... |
Show more